Coverage
-
September 23, 2014
A Florida federal judge on Monday denied a former Stiefel Laboratories Inc. executive's motion for a new trial after a jury found the company and its ex-CEO did not commit securities fraud by persuading him to sell back his stock at artificially low prices ahead of its 2009 acquisition by GlaxoSmithKline PLC.
2 other articles on this case.
View all »